GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (STU:ITH) » Definitions » Deferred Policy Acquisition Costs

Nektar Therapeutics (STU:ITH) Deferred Policy Acquisition Costs


View and export this data going back to 2013. Start your Free Trial

What is Nektar Therapeutics Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


Nektar Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.